For research use only. Not for therapeutic Use.
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation[1][2][3].
Evolocumab (5-100 μg/mL) can significantly prevent the cytotoxicity of H2O2 on human umbilical vein endothelial cells (HUVEC)[2].Evolocumab (100 μg/mL) can reduce the expression and secretion of inflammatory factors increased by stimulation of rat retinal Müller cells (RMC)[3].
| Catalog Number | I043758 |
| CAS Number | 1256937-27-5 |
| Purity | ≥95% |
| Reference | [1]. Fala L, et, al. Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia. Am Health Drug Benefits. 2016 Mar;9(Spec Feature):136-9. [2]. Zhou Q, et al. Protective effect of evolocumab on Müller cells in the rat retina under hyperglycaemic and hypoxic conditions. J Diabetes Complications. 2023 Oct;37(10):108593. [3]. Safaeian L, et al. Evolocumab, a PCSK9 inhibitor, protects human endothelial cells against H2O2-induced oxidative stress. Arch Physiol Biochem. 2022 Dec;128(6):1681-1686. |
